# Single-cell mass and growth-rate assays

Source: https://onco.cc/technologies/single-cell-mass-assays/  
OnCo record `single-cell-mass-assays` (Technology). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Repeated calibrated mass measurements can estimate a cell's growth rate; slower mass accumulation does not by itself show cell death.

## Summary

A suspended microchannel resonator weighs a cell relative to the fluid it displaces using the shift in a vibrating beam's frequency. Buoyant mass equals cell volume multiplied by the difference between cell and fluid density. It is not simply diameter or dry mass. Repeatedly measuring the same cell estimates mass accumulation rate; Godin reversed the flow to reintroduce the same cell to the sensor (a dynamic trap) and Cermak used serial sensors along one channel. Stevens investigated drug-response associations in specified cancer models and leukaemia samples, rather than universal clinical prediction.

## Fields

- Kind: Technology
- Status: emerging
- Last checked: 2026-11-10
- Principle: Calibrate a frequency shift to buoyant mass and track repeated readings from the same cell to estimate mass accumulation rate.

## Notes

- Assay card. Input: viable cells compatible with suspension and channel handling. Record source, identity, preparation losses, fluid and temperature conditions, exposure and observation interval. Calibration maps frequency shifts to mass, often picograms. Tracking repeated readings estimates a slope, often picograms per hour; mass-normalised rates have inverse-time units. Preparation and exposure consume finite material; the physical measurement can preserve cells, but recovery and downstream compatibility depend on the method.
- Quality and inference. Check clumps, cell attribution, instrument drift, calibration, tracking ambiguity and sufficient linked readings. Serial-sensor analyses exclude uncertain matches rather than invent a trajectory. Fluid-density changes can change buoyant mass. A small positive slope still indicates accumulation in the observed interval; later recovery, death and resistance need additional endpoints and time. Many measured cells from one specimen are not many independent patients. No universal rate cutoff establishes clinical sensitivity or immune recognition. Buoyant mass is also not a count of cell divisions. Physical measurement performance, a reproducible drug-response association and validated use for a clinical decision are separate kinds of evidence. Without extra measurements or assumptions, this sensor does not establish dry mass, a death mechanism, immune specificity or patient benefit.
- Fictional arithmetic. A tracked cell rising from 10 to 12 picograms over one hour has a slope of 2 picograms per hour. Comparable groups at 2 and 0.5 picograms per hour differ by (2 minus 0.5) divided by 2, or 75 percent. Both rates are positive. This is a rate reduction, not shrinkage, a killed-cell fraction or patient response. These values are invented.
- The positive research use is a rapid physical response readout and a view of cell-to-cell variation that a population average can conceal. Stevens measured short-term mass accumulation in specified cancer models and leukaemia samples; this can precede a large endpoint-count change, while slower accumulation can occur in living cells. A mixed specimen still requires attribution to the relevant population, and a mass sensor does not supply immune cells or recognition. Sources: https://pmc.ncbi.nlm.nih.gov/articles/PMC5142231/ ; https://pmc.ncbi.nlm.nih.gov/articles/PMC5064867/

## Sources

- Godin et al. 2010 buoyant-mass measurement: https://pmc.ncbi.nlm.nih.gov/articles/PMC2862099/
- Cermak et al. 2016 serial sensors and tracking: https://pmc.ncbi.nlm.nih.gov/articles/PMC5064867/
- Stevens et al. 2016 defined drug-response experiments: https://pmc.ncbi.nlm.nih.gov/articles/PMC5142231/

## Connected records

- fronts: [Diagnostics & Biomarkers](https://onco.cc/fronts/diagnostics/), [Drug Discovery Platforms](https://onco.cc/fronts/drug-discovery/)
- technologies: [Functional (ex vivo) drug testing](https://onco.cc/technologies/functional-drug-testing/)

---
JSON: https://onco.cc/api/v1/entities/single-cell-mass-assays.json